



The revival of the electrocardiogram in the stress imaging era: what European Society of Cardiology 2024 guidelines say (and don't say)

Emma Cerracchio*, Ettore Campagnano, Bruno Villari, Quirino Ciampi 

Cardiology Division, Fatebenefratelli Hospital, 82100 Benevento, Italy

***Correspondence:** Emma Cerracchio, Cardiology Division, Fatebenefratelli Hospital, 82100 Benevento, Italy. emma.cerracchio@gmail.com

Academic Editor: Undurti Das, UND Life Sciences, USA, Sri Ramachandra Medical University, India

Received: October 16, 2024 **Accepted:** April 9, 2025 **Published:** May 7, 2025

Cite this article: Cerracchio E, Campagnano E, Villari B, Ciampi Q. The revival of the electrocardiogram in the stress imaging era: what European Society of Cardiology 2024 guidelines say (and don't say). *Explor Cardiol.* 2025;3:101256. <https://doi.org/10.37349/ec.2025.101256>

Abstract

An electrocardiogram (ECG) is a vital diagnostic tool used during cardiac imaging stress testing to evaluate the heart's electrical activity under stress conditions. This combination of ECG and stress imaging testing provides comprehensive insights into cardiac function, particularly in detecting coronary artery disease (CAD) and assessing overall heart health. An ECG continuously monitors the heart's electrical signals, capturing data on heart rate, rhythm, and electrical conduction patterns. The value of the ECG in this context lies in its ability to detect ischemic changes, which occur when there is insufficient blood flow to the heart muscle due to narrowed or blocked coronary arteries, but also for coronary vasospasm or coronary microvascular disease. Specific ECG changes, such as ST-segment depression or elevation, and the appearance of arrhythmias, can indicate myocardial ischemia. These findings, when correlated with symptoms like chest pain or shortness of breath during the test, may provide strong evidence for CAD even in the absence of diagnostic abnormality of cardiac imaging with regional wall motion or perfusion changes. Additionally, the ECG helps identify other conditions that may manifest under stress, such as arrhythmias or conduction abnormalities, which might not be apparent at rest. The ECG's role extends beyond diagnosis. It helps stratify patients based on their risk of adverse cardiac events. For example, an abnormal ECG during a negative cardiac stress imaging test can suggest an increased likelihood of coronary calcification or abnormal coronary flow reserve and increased risk in the long term for cardiac events. In summary, the ECG is a valuable component of cardiac imaging stress testing. It provides real-time, non-invasive monitoring of the heart's electrical activity under stress, aiding in the diagnosis and risk assessment of CAD and other cardiac conditions. This enhances patient management by guiding treatment decisions and preventive strategies.

Keywords

Electrocardiogram, stress echocardiography, heart rate reserve, chronotropic incompetence



Introduction

The development of electrocardiogram (ECG) stress testing was a major advance in clinical cardiology [1]. Feil and Siegel recognized that myocardial ischemia and, thus, coronary artery disease (CAD) could be diagnosed by ST depression during exercise. Master and Oppenheimer developed the first standardized exercise test, a 1.5-minute step test to evaluate cardiac capacity and cardiovascular disease. Bruce developed the multi-stage treadmill test, now termed the Bruce protocol. An outcome study of Ellestad demonstrated that 1 mm of ST depression predicted cardiac events and death. Following one hundred years of development, the ECG remains the foundation of exercise stress testing [2, 3]. In the seventies, stress-ECG was also the natural approach of first-generation exercise-independent testing, such as dipyridamole [4, 5] or dobutamine stress [6], later popularized with cardiac imaging. In the cardiac imaging era, ECG stress testing progressively lost ground in favor of other markers of ischemia, more sensitive and earlier in the classical ischemic cascade of events in the presence of epicardial CAD [7–9]. In the last decade, it became progressively more obvious that even in the imaging era, ECG changes can offer surprisingly important diagnostic and prognostic information. Ischemia has multiple phenotypes in the real world [10], including ECG changes without cardiac imaging abnormality. The present narrative review will address the added value of ECG changes during stress in the cardiac imaging era, with a special focus on the different patterns of ECG changes (ST-segment depression, ST-segment elevation) in the presence of cardiac imaging normal or abnormal findings, the prevalence and meaning of arrhythmias during stress, and the pathophysiological and prognostic meaning of chronotropic incompetence during physical stress testing and during pharmacological stress testing where stress ECG is rarely used.

ST-segment depression and new regional wall motion abnormalities during stress echocardiography

In about 50% of patients with anatomically verified epicardial CAD and stress imaging positivity [with perfusion changes or regional wall motion abnormality (RWMA)], a diagnostic ST-segment depression develops during stress. In 178 patients with dipyridamole stress echo positivity, Cortigiani et al. [11] found that 59% of patients showed concomitant ST-segment depression, and these patients were 2 times more likely to have 3-vessel or left main CAD and 3 times more likely to have major adverse events in a 3-year follow-up. In the SE2030 study, Kobal et al. [12] found that stress-induced ischemic ECG changes during physical or pharmacological stress testing are associated with more extensive RWMA and blunted global left ventricular contractile reserve, with reduced coronary flow velocity reserve in the left anterior descending artery. These data were observed with different types of stress (exercise, dobutamine, vasodilators) and with the recruitment of 641 patients from 39 different sites in 10 countries, increasing the generalizability of the findings [12].

ST-segment depression without new RWMAs during stress echocardiography

ECG changes are relatively frequent during stress, and all physical and pharmacological tests currently employed with imaging techniques started their clinical and scientific life in combination with ECG in the pre-imaging era [1, 4, 6]. However, they were progressively abandoned in the imaging era since their diagnostic sensitivity and specificity are significantly lower if compared to cardiac imaging markers such as RWMA or perfusion changes [8, 9]. In a competitive view of the clinical use of different markers, cardiac imaging based on RWMA and/or perfusion outperforms ECG [13]. However, over the years it was evident that not a single marker was capable of capturing the diversity of phenotypes of inducible ischemia, and that ECG changes during vasodilators are even more suitable than RWMA in capturing a reduction in systemic endothelial dysfunction [14] in symptomatic patients with chronic coronary syndromes, or initial abnormalities of coronary calcification in asymptomatic subjects [15]. More than 20 years ago, a distinguished clinical cardiologist commented on these results, suggesting a revival of the ECG in the imaging era [16]. Subsequent extensive evidence in different patients' subsets corroborated this visionary editorial comment [17]. ST-segment depression during dobutamine, exercise, or dipyridamole is associated with a worse prognosis even when it occurs in the absence of RWMA or perfusion changes [18].

Nine studies with a total of 23,715 patients were included in a recent meta-analysis. The primary outcome was a composite of all-cause death or myocardial infarction. The primary endpoint was more common with discordant results (ECG positivity with stress imaging negativity) with exercise stress echocardiography [relative risk 1.33, 95% CI (1.08–1.63)] or pharmacological SPECT [relative risk 6.53, 95% CI (2.31–18.48)] [19].

ST-segment depression without new RWMAs during stress echocardiography in ANOCA patients

Recently, a paper was published on JACC showing that ECG abnormality with ST-segment depression during stress is frequently associated with a reduction of coronary flow velocity reserve and abnormal coronary vasomotor function in patients with angiographically normal coronary arteries [20]. Interestingly, the concept of ECG lies (false positivity for a coronary anatomic gold standard) becoming physiologic truth when a physiology or prognostic gold standard is adopted is at least 40 years old, and well described in the alternative ischemic cascade already 20 years ago [21–25].

Dipyridamole-induced ST-segment depression is frequently elicited in hypertensive patients when angiographically assessed coronary disease is absent. This ischemic-like electrocardiographic response can be found in left ventricular hypertrophy. However, even when the left ventricular mass is normal, dipyridamole-induced ST-segment depression is associated with an impaired coronary flow response to pacing, which is consistent with microvascular disease.

In special subsets beyond CAD, such as patients with hypertrophic cardiomyopathy without CAD, a solitary (without RWMA) ST-segment depression during stress identifies patients at high risk of subsequent death [26, 27]. In patients with heart transplants, a solitary ST-segment depression identified during pharmacological stress identifies patients with acute rejection, even without inducible RWMA [28].

ST-segment elevation as a marker of coronary vasospasm

ST-segment depression is by far the most common ECG pattern but 1% to 3 % of ECG positivity is accompanied by ST-segment elevation (in absence of resting Q wave) which indicates coronary vasospasm, most frequently at peak of stress (exercise or dobutamine) [29, 30] or immediately in the early recovery phase at the stop of exercise or early recovery phase, or with dobutamine after beta-blockers [31, 32], or with dipyridamole after aminophylline [33, 34]. This information is clinically important since, if missed, the further administration of an antidote can exacerbate vasospasm, favoring the transition to myocardial infarction. The vasospastic mechanism, if recognized, leads to the administration of intravenous nitrates or sublingual nifedipine, promptly resolving the coronary vasospasm in most cases.

Heart rate reserve: a simple predictor of mortality

Heart rate reserve is one of the simplest markers of risk during stress. It is easy to acquire since a simple one-lead ECG on the echo monitor is sufficient to obtain all the information needed. It is extraordinarily simple to analyze, since only the rest and peak value of the heart rate are utilized, and the heart rate is displayed automatically online in the echo monitor. It has an impressive amount of evidence behind its clinical use since it was first shown to predict all-cause death in 1975 by the father of stress testing, Ellestad. In a landmark paper published in *Circulation*, Ellestad and Wan [35] assembled follow-up data in 2,700 patients with exercise stress tests and showed that those with chronotropic incompetence had a high incidence of coronary events even though the ECG response to exercise was normal. This finding was confirmed over the subsequent decades [36, 37], and progressively extended to models beyond CAD such as heart failure [38, 39] or hypertrophic cardiomyopathy [40, 41] or transthyretin amyloidosis [42] and to stresses other than exercise such as dobutamine [43, 44] and vasodilators [45–53]. A blunted heart rate reserve is a strong predictor of all cause-death, especially of sudden death, and its value is additive and incremental over cardiac stress imaging information provided by perfusion defect or wall motion abnormality [54, 55].

Insufficient heart rate increase due to chronotropic incompetence is considered a major contributor to exercise and functional intolerance in heart failure, resulting from an imbalanced autonomic nervous system, which is chronically shifted toward sympathetic overactivation, leading to down-regulation and desensitization of cardiac β -receptors [56, 57].

It is additive because it focuses on a specific vulnerability, different from critical epicardial coronary artery stenosis or coronary microvascular dysfunction. It is the cardiac sympathetic reserve, elicited by endogenous catecholamines or exogenous catecholamines such as dobutamine or endogenous or exogenous adenosine accumulation stimulating A2a receptors present on the carotid body and increasing efferent sympathetic efflux to the heart, eventually increasing heart rate [58–62]. The greater the increase in heart rate, the higher the cardiac sympathetic reserve, and this problem is a universal feature of vulnerability across all types of disease (Figure 1). This simple parameter has 100% feasibility, 0% variability, and prognostic strength higher than RWMA and coronary flow velocity reserve, and much more user-friendly than all methods used to assess cardiac autonomic function in the clinical arena [63, 64].




Figure 1. HRR as a marker of sympathetic dysfunction in several cardiovascular conditions. ECG: electrocardiogram; HRR: heart rate reserve

Conclusions

In the 2016 joint recommendation of the European Association of Cardiovascular Imaging and the American Society of Echocardiography of stress echo applications beyond CAD, chronotropic incompetence during exercise is considered an alternative explanation for symptoms of exercise and an exclusion criterion for the correct diagnosis of heart failure with preserved ejection fraction [65]. Before including this diagnosis, one should exclude exercise-induced ischemia with new wall motion abnormalities, dynamic severe mitral regurgitation during stress, development of left ventricular outflow tract obstruction, and insufficient increase in heart rate. In the recently released 2024 recommendations of European Association of Cardiovascular Imaging on the clinical use of stress echocardiography, heart rate reserve is incorporated as a pillar of the ABCDE protocol, with E standing for ECG-based assessment of chronotropic incompetence measured with heart rate reserve with all stresses in all patients, from chronic coronary syndromes to heart failure and hypertrophic cardiomyopathy [9]. Guidelines of the European Society of Cardiology on chronic coronary syndromes, in individuals with an initially low (> 5–15%) likelihood of obstructive CAD, exercise ECG, and detection of atherosclerotic disease in non-coronary arteries may be considered to adjust the pre-test likelihood estimate (IIb C). For the diagnosis of disease progression in patients with established chronic coronary syndrome, with new or worsening symptoms, it is now recommended to use stress imaging (I C). The second, still legitimate, choice of using “*alternatively, exercise ECG*”—present in the 2019

ESC recommendations, has been deleted. For the initial evaluation of patients with chest pain, exercise-ECG is recommended “*in selected patients*” [66]. Guidelines state that “*Exercise ECG testing may modify the likelihood of obstructive CAD and can be used in patients with low (> 5%–15%) clinical likelihood, in whom a negative test allows reclassification to the very low (\leq 5%) clinical likelihood group with a favorable prognosis. Exercise ECG testing has a lower diagnostic performance of obstructive CAD compared with modern functional imaging and CCTA, which, therefore, should be preferred as a first-line test in subjects with suspected CCS.*”

Exercise ECG is recommended in selected patients for the assessment of exercise tolerance, symptoms, arrhythmias, blood pressure response, and event risk. Interestingly, guidelines completely miss the information on heart rate reserve. However, if we consider the value (outcome/cost) [67] and even more, the sustainability (outcome/cost + radiation + carbon footprint) of testing, as we probably should [68], exercise ECG is the first-line obligatory cornerstone of diagnosis and risk stratification of the patient with known or suspected chronic coronary syndromes. Exercise is the only physiologic and by far the safest stress, and is fundamental not only for diagnosis but also for risk stratification. A maximal exercise ECG assesses ischemic vulnerability (with ST-segment and angina), arrhythmic vulnerability, hemodynamic vulnerability (with excessive hypertension or blood pressure drop), and cardiac autonomic system vulnerability (with heart rate reserve for sympathetic reserve and heart rate recovery for parasympathetic reserve) (Figure 2).




Figure 2. The many functional vulnerabilities identified by a simple exercise-ECG test. HR: heart rate; ECG: electrocardiogram

Even in modern cardiology, it is difficult to obtain so much with so little investment of time and money.

Our review provides an overview of the diagnostic and prognostic role of ECG during stress in the new cardiac imaging era. With the advances in cardiac imaging in both functional and anatomic fronts and the existing limitations of exercise stress testing, this modality appears less favoured worldwide, as reflected in recent guidelines. Instead, the combination of stress-ECG and imaging modalities provides the clinician a wealth of information to identify different phenotypes of inducible ischemia and to better risk-stratify patients (Figure 3). Chronotropic incompetence is another important marker of vulnerability that can emerge during stress. Heart rate reserve is a strong predictor of outcomes, especially sudden death, not only in CAD but in many other cardiovascular conditions, especially heart failure. In summary, the ECG

represents a ubiquitous, noninvasive, and low-cost functional test for a comprehensive risk assessment in patients with CAD and other cardiac conditions. This improves patient management by guiding treatment decisions and preventive strategies.




Figure 3. Central illustration. An example of a patient with positive ABCDE dipyridamole stress: induced ST-segment depression, new wall motion abnormalities (WMSI, step A positive), B lines at peak stress (step B positive), abnormal left ventricular contractile reserve (LVCR, step C positive) reduced coronary flow velocity reserve (CFVR, step D positive). RWMA: regional wall motion abnormality; LVCR: left ventricular contractile reserve; CFVR: coronary flow velocity reserve; CFR: coronary flow reserve; HRR: heart rate reserve; Δ WMSI: average wall motion score index; WMSI: wall motion score index; HR: heart rate

Abbreviations

CAD: coronary artery disease

ECG: electrocardiogram

RWMA: regional wall motion abnormality

Declarations

Author contributions

E Cerracchio: Writing—review & editing. E Campagnano: Data curation. BV: Supervision. QC: Conceptualization, Supervision, Writing—review & editing. All authors read and approved the submitted version.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Ethical approval

The study in the central illustration was approved by the Ethics Committee Lazio 1 [prot n. 295, 8/3/2021] and complies with the Declaration of Helsinki.

Consent to participate

Informed consent to participate for the study in the central illustration was obtained from all participants.

Consent to publication

Not applicable.

Availability of data and materials

The data for Central Illustration could be available from the corresponding authors upon reasonable request.

Funding

Not applicable.

Copyright

© The Author(s) 2025.

Publisher's note

Open Exploration maintains a neutral stance on jurisdictional claims in published institutional affiliations and maps. All opinions expressed in this article are the personal views of the author(s) and do not represent the stance of the editorial team or the publisher.

References

1. Gregory S. Thomas, Paul Kligfield, Myrvin H. Ellestad History of exercise stress testing. In: Ellestad's stress testing: principles and practice. Thomas GS, Wann S, Ellestad M, editors. 6th edition. New York: Oxford Academic; 2018. [\[DOI\]](#)
2. Fletcher GF, Ades PA, Kligfield P, Arena R, Balady GJ, Bittner VA, et al.; American Heart Association Exercise; Cardiac Rehabilitation; and Prevention Committee of the Council on Clinical Cardiology; Council on Nutrition, Physical Activity and Metabolism, Council on Cardiovascular and Stroke Nursing, and Council on Epidemiology and Prevention. Exercise standards for testing and training: a scientific statement from the American Heart Association. *Circulation*. 2013;128:873–934. [\[DOI\]](#) [\[PubMed\]](#)
3. Gulati M, Levy PD, Mukherjee D, Amsterdam E, Bhatt DL, Birtcher KK, et al. 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *Circulation*. 2021;144:e368–454. [\[DOI\]](#) [\[PubMed\]](#)
4. Tauchert M, Behrenbeck DW, Hötzel J, Hilger HH. A new pharmacological test for diagnosing coronary artery disease (author's transl). *Dtsch Med Wochenschr*. 1976;101:35–7. [\[DOI\]](#) [\[PubMed\]](#)
5. Tavazzi L, Previtalli M, Salerno JA, Chimienti M, Ray M, Medici A, et al. Dipyridamole test in angina pectoris: diagnostic value and pathophysiological implications. *Cardiology*. 1982;69:34–41. [\[DOI\]](#) [\[PubMed\]](#)
6. Coma-Canella I. Dobutamine stress test to diagnose the presence and severity of coronary artery lesions in angina. *Eur Heart J*. 1991;12:1198–204. [\[DOI\]](#) [\[PubMed\]](#)

7. Nesto RW, Kowalchuk GJ. The ischemic cascade: temporal sequence of hemodynamic, electrocardiographic and symptomatic expressions of ischemia. *Am J Cardiol.* 1987;59:23C–30C. [DOI] [PubMed]
8. Pellikka PA, Arruda-Olson A, Chaudhry FA, Chen MH, Marshall JE, Porter TR, et al. Guidelines for Performance, Interpretation, and Application of Stress Echocardiography in Ischemic Heart Disease: From the American Society of Echocardiography. *J Am Soc Echocardiogr.* 2020;33:1–41.e8. [DOI] [PubMed]
9. Picano E, Pierard L, Peteiro J, Djordjevic-Dikic A, Sade LE, Cortigiani L, et al. The clinical use of stress echocardiography in chronic coronary syndromes and beyond coronary artery disease: a clinical consensus statement from the European Association of Cardiovascular Imaging of the ESC. *Eur Heart J Cardiovasc Imaging.* 2024;25:e65–90. [DOI] [PubMed]
10. Gaibazzi N, Ciampi Q, Cortigiani L, Wierzbowska-Drabik K, Zagatina A, Djordjevic-Dikic A, et al.; Stress Echo 2030 Study Group. Multiple Phenotypes of Chronic Coronary Syndromes Identified by ABCDE Stress Echocardiography. *J Am Soc Echocardiogr.* 2024;37:477–85. [DOI] [PubMed]
11. Cortigiani L, Lombardi M, Michelassi C, Paolini EA, Nannini E. Significance of myocardial ischemic electrocardiographic changes during dipyridamole stress echocardiography. *Am J Cardiol.* 1998;82: 1008–12. [DOI] [PubMed]
12. Kobal S, Arbucci R, Zagatina A, Padang R, Peteiro Vazquez J, Boshchenko A, et al. Functional correlates of ischemic electrocardiographic changes during stress echocardiography. data from stress echo 2030 survey. *Eur Heart J.* 2024;45:ehae666.056. [DOI]
13. Picano E. Stress echocardiography. From pathophysiological toy to diagnostic tool. *Circulation.* 1992; 85:1604–12. [DOI] [PubMed]
14. Pálincás A, Tóth E, Amyot R, Rigo F, Venneri L, Picano E. The value of ECG and echocardiography during stress testing for identifying systemic endothelial dysfunction and epicardial artery stenosis. *Eur Heart J.* 2002;23:1587–95. [DOI] [PubMed]
15. Daubert MA, Sivak J, Dunning A, Douglas PS, Coyne B, Wang TY, et al. Implications of Abnormal Exercise Electrocardiography With Normal Stress Echocardiography. *JAMA Intern Med.* 2020;180: 494–502. [DOI] [PubMed] [PMC]
16. Duran JM, Shrader P, Hong C, Haddad F, Santana EJ, Cauwenberghs N, et al.; Project Baseline Health Study Group. Abnormal Exercise Electrocardiography With Normal Stress Echocardiography Is Associated With Subclinical Coronary Atherosclerosis. *Circ Cardiovasc Imaging.* 2025;18:e017380. [DOI] [PubMed]
17. Préda I. Differentiation between endothelial dysfunction and epicardial coronary artery stenosis with the aid of stress ECG and echocardiography. A novel return of the old ECG! *Eur Heart J.* 2002;23: 1561–2. [DOI] [PubMed]
18. Ranasinghe S, Tjoe B, Shufelt C, Wei J, Lauzon M, Luu J, et al. Association of abnormal electrocardiography response on dobutamine stress echocardiogram with longer-term major adverse cardiovascular events in women with symptoms of ischemic heart disease. *Cardiovasc Diagn Ther.* 2023;13:948–55. [DOI] [PubMed] [PMC]
19. Mansour M, Alqaisi O, Gautam N, Vallurupalli S. Significance of abnormal stress electrocardiography with normal cardiac imaging during stress testing-a meta-analysis. *J Electrocardiol.* 2024;83:64–70. [DOI] [PubMed]
20. Sinha A, Dutta U, Demir OM, Silva KD, Ellis H, Belford S, et al. Rethinking False Positive Exercise Electrocardiographic Stress Tests by Assessing Coronary Microvascular Function. *J Am Coll Cardiol.* 2024;83:291–9. [DOI] [PubMed] [PMC]
21. Osterspey A, Jansen W, Tauchert M, Eigl J, Höpp H, Behrenbeck DW, et al. [Value of the dipyridamole test in the diagnosis of coronary heart disease. Comparison with the stress ECG and coronary angiogram]. *Dtsch Med Wochenschr.* 1983;108:1469–74. [DOI] [PubMed]

22. Lucarini AR, Picano E, Lattanzi F, Camici P, Marini C, Salvetti A, et al. Dipyridamole echocardiography stress testing in hypertensive patients. Targets and tools. *Circulation*. 1991;83:III68–72. [\[PubMed\]](#)
23. Scheler S, Motz W, Strauer BE. Mechanism of angina pectoris in patients with systemic hypertension and normal epicardial coronary arteries by arteriogram. *Am J Cardiol*. 1994;73:478–82. [\[DOI\]](#) [\[PubMed\]](#)
24. Youn H, Park C, Cho E, Jung H, Jeon H, Lee J, et al. Pattern of exercise-induced ST change is related to coronary flow reserve in patients with chest pain and normal coronary angiogram. *Int J Cardiol*. 2005; 101:299–304. [\[DOI\]](#) [\[PubMed\]](#)
25. Ong P, Athanasiadis A, Hill S, Schäufele T, Mahrholdt H, Sechtem U. Coronary microvascular dysfunction assessed by intracoronary acetylcholine provocation testing is a frequent cause of ischemia and angina in patients with exercise-induced electrocardiographic changes and unobstructed coronary arteries. *Clin Cardiol*. 2014;37:462–7. [\[DOI\]](#) [\[PubMed\]](#) [\[PMC\]](#)
26. Lazzeroni E, Picano E, Morozzi L, Maurizio AR, Palma G, Ceriati R, et al. Dipyridamole-induced ischemia as a prognostic marker of future adverse cardiac events in adult patients with hypertrophic cardiomyopathy. Echo Persantine Italian Cooperative (EPIC) Study Group, Subproject Hypertrophic Cardiomyopathy. *Circulation*. 1997;96:4268–72. [\[DOI\]](#) [\[PubMed\]](#)
27. Dilsizian V, Bonow RO, Epstein SE, Fananapazir L. Myocardial ischemia detected by thallium scintigraphy is frequently related to cardiac arrest and syncope in young patients with hypertrophic cardiomyopathy. *J Am Coll Cardiol*. 1993;22:796–804. [\[DOI\]](#) [\[PubMed\]](#)
28. Picano E, Pieri GD, Salerno JA, Arbustini E, Distante A, Martinelli L, et al. Electrocardiographic changes suggestive of myocardial ischemia elicited by dipyridamole infusion in acute rejection early after heart transplantation. *Circulation*. 1990;81:72–7. [\[DOI\]](#) [\[PubMed\]](#)
29. Specchia G, Servi Sd, Falcone C, Angoli L, Mussini A, Bramucci E, et al. Significance of exercise-induced ST-segment elevation in patients without myocardial infarction. *Circulation*. 1981;63:46–53. [\[DOI\]](#) [\[PubMed\]](#)
30. Waters DD, Szlachcic J, Bourassa MG, Scholl JM, Thérioux P. Exercise testing in patients with variant angina: results, correlation with clinical and angiographic features and prognostic significance. *Circulation*. 1982;65:265–74. [\[DOI\]](#) [\[PubMed\]](#)
31. Previtati M, Fétiveau R, Lanzarini L, Cavalotti C. Dobutamine-induced ST-segment elevation in patients without myocardial infarction. *Am J Cardiol*. 1998;82:1528–30, A7. [\[DOI\]](#) [\[PubMed\]](#)
32. Kawano H, Fujii H, Motoyama T, Kugiyama K, Ogawa H, Yasue H. Myocardial ischemia due to coronary artery spasm during dobutamine stress echocardiography. *Am J Cardiol*. 2000;85:26–30. [\[DOI\]](#) [\[PubMed\]](#)
33. Picano E, Lattanzi F, Masini M, Distante A, L'Abbate A. Aminophylline termination of dipyridamole stress as a trigger of coronary vasospasm in variant angina. *Am J Cardiol*. 1988;62:694–7. [\[DOI\]](#) [\[PubMed\]](#)
34. Díaz-Castro O, Fernández-López J, Campos L, Calvo F, Mantilla R, Goicolea J. ST segment elevation during dipyridamole stress testing in a patient without coronary lesions. *Rev Esp Cardiol*. 2004;57: 177–9. [\[PubMed\]](#)
35. Ellestad MH, Wan MK. Predictive implications of stress testing. Follow-up of 2700 subjects after maximum treadmill stress testing. *Circulation*. 1975;51:363–9. [\[DOI\]](#) [\[PubMed\]](#)
36. Lauer MS, Francis GS, Okin PM, Pashkow FJ, Snader CE, Marwick TH. Impaired chronotropic response to exercise stress testing as a predictor of mortality. *JAMA*. 1999;281:524–9. [\[DOI\]](#) [\[PubMed\]](#)
37. Gulati M, Shaw LJ, Thisted RA, Black HR, Merz CNB, Arnsdorf MF. Heart rate response to exercise stress testing in asymptomatic women: the St. James women take heart project. *Circulation*. 2010;122: 130–7. [\[DOI\]](#) [\[PubMed\]](#)
38. Benes J, Kotrc M, Borlaug BA, Lefflerova K, Jarolim P, Bendlova B, et al. Resting heart rate and heart rate reserve in advanced heart failure have distinct pathophysiologic correlates and prognostic impact: a prospective pilot study. *JACC Heart Fail*. 2013;1:259–66. [\[DOI\]](#) [\[PubMed\]](#)

39. Sarma S, Howden E, Lawley J, Samels M, Levine BD. Central Command and the Regulation of Exercise Heart Rate Response in Heart Failure With Preserved Ejection Fraction. *Circulation*. 2021;143:783–9. [\[DOI\]](#) [\[PubMed\]](#) [\[PMC\]](#)
40. Efthimiadis GK, Giannakoulas G, Parcharidou DG, Pagourelas ED, Kouidi EJ, Spanos G, et al. Chronotropic incompetence and its relation to exercise intolerance in hypertrophic cardiomyopathy. *Int J Cardiol*. 2011;153:179–84. [\[DOI\]](#) [\[PubMed\]](#)
41. Ciampi Q, Olivotto I, Peteiro J, D'Alfonso MG, Mori F, Tasseti L, et al.; The Stress Echo Study Group On Behalf Of The Italian Society Of Echocardiography And Cardiovascular Imaging Siecvi. Prognostic Value of Reduced Heart Rate Reserve during Exercise in Hypertrophic Cardiomyopathy. *J Clin Med*. 2021;10:1347. [\[DOI\]](#) [\[PubMed\]](#) [\[PMC\]](#)
42. Patel RK, Bandera F, Venneri L, Porcari A, Razvi Y, Ioannou A, et al. Cardiopulmonary Exercise Testing in Evaluating Transthyretin Amyloidosis. *JAMA Cardiol*. 2024;9:367–76. [\[DOI\]](#) [\[PubMed\]](#) [\[PMC\]](#)
43. Elhendy A, Mahoney DW, Khandheria BK, Burger K, Pellikka PA. Prognostic significance of impairment of heart rate response to exercise: impact of left ventricular function and myocardial ischemia. *J Am Coll Cardiol*. 2003;42:823–30. [\[DOI\]](#) [\[PubMed\]](#)
44. Chaowalit N, McCully RB, Callahan MJ, Mookadam F, Bailey KR, Pellikka PA. Outcomes after normal dobutamine stress echocardiography and predictors of adverse events: long-term follow-up of 3014 patients. *Eur Heart J*. 2006;27:3039–44. [\[DOI\]](#) [\[PubMed\]](#)
45. Hage FG, Iskandrian AE. Heart rate response during vasodilator stress myocardial perfusion imaging: Mechanisms and implications. *J Nucl Cardiol*. 2010;17:536–9. [\[DOI\]](#) [\[PubMed\]](#)
46. Cortigiani L, Carpeggiani C, Landi P, Raciti M, Bovenzi F, Picano E. Usefulness of Blunted Heart Rate Reserve as an Imaging-Independent Prognostic Predictor During Dipyridamole Stress Echocardiography. *Am J Cardiol*. 2019;124:972–7. [\[DOI\]](#) [\[PubMed\]](#)
47. Cortigiani L, Carpeggiani C, Landi P, Raciti M, Bovenzi F, Picano E. Prognostic Value of Heart Rate Reserve in Patients with Permanent Atrial Fibrillation during Dipyridamole Stress Echocardiography. *Am J Cardiol*. 2020;125:1661–5. [\[DOI\]](#) [\[PubMed\]](#)
48. Cortigiani L, Ciampi Q, Carpeggiani C, Bovenzi F, Picano E. Prognostic value of heart rate reserve is additive to coronary flow velocity reserve during dipyridamole stress echocardiography. *Arch Cardiovasc Dis*. 2020;113:244–51. [\[DOI\]](#) [\[PubMed\]](#)
49. Cortigiani L, Carpeggiani C, Landi P, Raciti M, Bovenzi F, Picano E, et al. Prognostic Value of Heart Rate Reserve during Dipyridamole Stress Echocardiography in Patients With Abnormal Chronotropic Response to Exercise. *Am J Cardiol*. 2021;154:106–10. [\[DOI\]](#) [\[PubMed\]](#)
50. Cortigiani L, Carpeggiani C, Meola L, Djordjevic-Dikic A, Bovenzi F, Picano E. Reduced Sympathetic Reserve Detectable by Heart Rate Response after Dipyridamole in Anginal Patients with Normal Coronary Arteries. *J Clin Med*. 2021;11:52. [\[DOI\]](#) [\[PubMed\]](#) [\[PMC\]](#)
51. Cortigiani L, Ciampi Q, Carpeggiani C, Lisi C, Bovenzi F, Picano E. Additional prognostic value of heart rate reserve over left ventricular contractile reserve and coronary flow velocity reserve in diabetic patients with negative vasodilator stress echocardiography by regional wall motion criteria. *Eur Heart J Cardiovasc Imaging*. 2022;23:209–16. [\[DOI\]](#) [\[PubMed\]](#)
52. Daros CB, Ciampi Q, Cortigiani L, Gaibazzi N, Rigo F, Wierzbowska-Drabik K, et al.; On Behalf Of The Stress Echo Study Group Of The Italian Society Of Echocardiography And Cardiovascular Imaging. Coronary Flow, Left Ventricular Contractile and Heart Rate Reserve in Non-Ischemic Heart Failure. *J Clin Med*. 2021;10:3405. [\[DOI\]](#) [\[PubMed\]](#) [\[PMC\]](#)
53. Ciampi Q, Zagatina A, Cortigiani L, Wierzbowska-Drabik K, Kasprzak JD, Haberka M, et al. Prognostic value of stress echocardiography assessed by the ABCDE protocol. *Eur Heart J*. 2021;42:3869–78. [\[DOI\]](#) [\[PubMed\]](#) [\[PMC\]](#)
54. Brubaker PH, Kitzman DW. Chronotropic incompetence: causes, consequences, and management. *Circulation*. 2011;123:1010–20. [\[DOI\]](#) [\[PubMed\]](#) [\[PMC\]](#)

55. Fukuda K, Kanazawa H, Aizawa Y, Ardell JL, Shivkumar K. Cardiac innervation and sudden cardiac death. *Circ Res*. 2015;116:2005–19. [DOI] [PubMed] [PMC]
56. Ohshima S, Isobe S, Izawa H, Nanasato M, Ando A, Yamada A, et al. Cardiac sympathetic dysfunction correlates with abnormal myocardial contractile reserve in dilated cardiomyopathy patients. *J Am Coll Cardiol*. 2005;46:2061–8. [DOI] [PubMed]
57. Isobe S, Izawa H, Iwase M, Nanasato M, Nonokawa M, Ando A, et al. Cardiac 123I-MIBG reflects left ventricular functional reserve in patients with nonobstructive hypertrophic cardiomyopathy. *J Nucl Med*. 2005;46:909–16. [PubMed]
58. Laghi-Pasini F, Guideri F, Petersen C, Lazzerini PE, Sicari R, Capecchi PL, et al. Blunted increase in plasma adenosine levels following dipyridamole stress in dilated cardiomyopathy patients. *J Intern Med*. 2003;254:591–6. [DOI] [PubMed]
59. Lucarini AR, Picano E, Marini C, Favilla S, Salvetti A, Distante A. Activation of sympathetic tone during dipyridamole test. *Chest*. 1992;102:444–7. [DOI] [PubMed]
60. Biaggioni I, Killian TJ, Mosqueda-Garcia R, Robertson RM, Robertson D. Adenosine increases sympathetic nerve traffic in humans. *Circulation*. 1991;83:1668–75. [DOI] [PubMed]
61. Petrucci E, Mainardi LT, Balian V, Ghiringhelli S, Bianchi AM, Bertinelli M, et al. Assessment of heart rate variability changes during dipyridamole infusion and dipyridamole-induced myocardial ischemia: a time variant spectral approach. *J Am Coll Cardiol*. 1996;28:924–34. [DOI] [PubMed]
62. Bombardini T, Pacini D, Potena L, Maccherini M, Kovacevic-Preradovic T, Picano E. Heart rate reserve during dipyridamole stress test applied to potential heart donors in brain death. *Minerva Cardioangiol*. 2020;68:249–57. [DOI] [PubMed]
63. Zygmunt A, Stanczyk J. Methods of evaluation of autonomic nervous system function. *Arch Med Sci*. 2010;6:11–8. [DOI] [PubMed] [PMC]
64. Kusumoto FM, Schoenfeld MH, Barrett C, Edgerton JR, Ellenbogen KA, Gold MR, et al. 2018 ACC/AHA/HRS Guideline on the Evaluation and Management of Patients With Bradycardia and Cardiac Conduction Delay: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. *Circulation*. 2019;140:e382–482. [DOI] [PubMed]
65. Lancellotti P, Pellikka PA, Budts W, Chaudhry FA, Donal E, Dulgheru R, et al. The clinical use of stress echocardiography in non-ischaemic heart disease: recommendations from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. *Eur Heart J Cardiovasc Imaging*. 2016;17:1191–229. [DOI] [PubMed]
66. Vrints C, Andreotti F, Koskinas KC, Rossello X, Adamo M, Ainslie J, et al.; ESC Scientific Document Group (2024). 2024 ESC Guidelines for the management of chronic coronary syndromes: Developed by the task force for the management of chronic coronary syndromes of the European Society of Cardiology (ESC) Endorsed by the European Association for Cardio-Thoracic Surgery (EACTS). *Eur Heart J*. 2024;45:3415–537. [DOI] [PubMed]
67. Porter ME. A strategy for health care reform--toward a value-based system. *N Engl J Med*. 2009;361:109–12. [DOI] [PubMed]
68. Picano E. Economic, ethical, and environmental sustainability of cardiac imaging. *Eur Heart J*. 2023;44:4748–51. [DOI] [PubMed]